Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Unintended Consequences Of REMS Weighed On Entyvio Review Team

24 Oct 2014

• By Bridget Silverman

Related Content

MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy

01 Mar 2011

Legacy Cost: Takeda’s <em>Entyvio</em> Development Shaped By <em>Tysabri</em> Fallout

24 Oct 2014

FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures

12 May 2014

Alexion’s Soliris REMS Gets FDA Panel Review In Wider Evaluation Effort

07 Oct 2014

Related Companies

Takeda Pharmaceutical Co. Ltd.

Biogen, Inc.

Additional Topics

Risk Management Approvals BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.